However, since CD155-TIGIT interaction contributes to cancer resistance to PD-1 blockade (35, 36), inhibition of TIGIT may be a promising strategy to increase the efficacy of PD-1 blockade therapy, especially to combat PD-1 inhibitor resistant tumors (37). The gene discussed is PVR; the disease is cancer.